Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Research & Development of $5.2 million for Q1 2026, down 21.45% year-over-year from $6.6 million in Q1 2025, and up 5.13% quarter-over-quarter from $4.9 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Research & Development history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Research & Development fell 21.45% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $18.8 million (down 26.77% YoY), while the FY2025 annual figure was $20.2 million, down 24.27% from the prior year.
- Research & Development for Q1 2026 stood at $5.2 million, up from $4.9 million in the prior quarter.
- The five-year high for Research & Development was $11.2 million in Q3 2023, with the low at $3.2 million in Q3 2025.
- The 5-year median for Research & Development is $7.6 million (2024), against an average of $7.5 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 153.47% in 2022, then tumbled 47.81% in 2025.
- Rani Therapeutics Holdings' Research & Development stood at $10.4 million in 2022, then decreased by 26.77% to $7.6 million in 2023, then dropped by 10.47% to $6.8 million in 2024, then retreated by 27.91% to $4.9 million in 2025, then rose by 5.13% to $5.2 million in 2026.
- Business Quant data shows RANI's Research & Development at $5.2 million in Q1 2026, $4.9 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 5.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.02 Mn |
| Mar 31, 2026 | 5.16 Mn |
| Dec 31, 2025 | 4.91 Mn |
| Sep 30, 2025 | 3.22 Mn |
| Jun 30, 2025 | 5.51 Mn |
| Mar 31, 2025 | 6.57 Mn |
| Dec 31, 2024 | 6.81 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Jun 30, 2024 | 6.12 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Dec 31, 2023 | 7.61 Mn |
| Sep 30, 2023 | 11.22 Mn |
| Jun 30, 2023 | 11.09 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Dec 31, 2022 | 10.39 Mn |
| Sep 30, 2022 | 9.10 Mn |
| Jun 30, 2022 | 9.53 Mn |
| Mar 31, 2022 | 7.59 Mn |
| Dec 31, 2021 | 7.42 Mn |
| Sep 30, 2021 | 11.96 Mn |